Royal jelly (RJ) is widely used as a food supplement for anti-aging and beauty. However, its use has been linked to asthma and hemorrhagic colitis. Since its mechanisms of toxicity have not been fully identified, we conducted an investigation to elucidate its molecular and cytogenetic effects. Using human lymphocytes in vitro, treatments with RJ (0.0005-5 mg/ml) for 3 h did not induce sister chromatid exchanges until 5 mg/ml was used. Treatments for 24 h showed a dose-dependent reduction in BCL2/BAX, c-MYC/BAX and HO-1/BAX ratios. The exception was the NRF2/BAX ratio, showing a dose-dependent reduction at low doses, but a marked increase at the highest dose. The hTERT/BAX ratio was maintained at approximately a 1.2-fold increase but decreased to nearly normal at the highest dose. Our findings indicated that the lowest dose of RJ treatment provided maximum benefits, mainly through hTERT activation relating to prolonged lifespan. The highest dose of RJ inhibited cell survival, cell proliferation and an antioxidative enzyme; nevertheless, it still activated an antioxidative response through NRF2 and maintained telomeres during cell crisis. RJ treatment at 0.05 mg/ml increased cyclin E, BCL2 and BAX to maximum levels indicating that throughout the active cell cycle, both cell survival and cell apoptosis increased. Using the gene expression ratios over BAX, similar to BCL2/BAX, provided more informative data than using individual protein levels alone. With these informative ratios, our results confirm the potential benefits of RJ in enhancing lifespan and activation antioxidative power. Further, in vivo mechanistic studies will be useful in validating these results.
Introduction
Natural products are increasingly used worldwide for health benefits. They have demonstrated physiological benefits, reduced risk of chronic diseases and provided savings in healthcare. As benefits have often been exaggerated, more scientific studies are needed to validate claims.
Royal jelly (RJ), a milky-acid secretion from worker honeybees, is fed to all larvae for the first 3 days, and only larvae that become queens receive RJ throughout their life. The queen bee is the only sexually mature female in a hive and has the biggest size and the longest life. RJ contains nutritious substances, rich in various vitamins, amino acids, special fatty acids, sugars and polyphenols. It has traditionally been used in many ancient civilisations, such as Greece, Egypt and China to promote long life, enhance libido and restore vitality and beauty (1) . Studies have been written on its biological and pharmacological actions e.g. antibacterial (2) , antitumor (3) and antifatigue (4) . It increased the life span of mice (5) and stimulated the growth of human myeloid cell line (6) . Ingestion of RJ for 6 months in healthy volunteers showed improved erythropoiesis, and mental health (7) . However, reported side effects had included asthma, anaphylaxis and hemorrhagic colitis (8, 9) . Therefore, more research on mechanisms of action of RJ is needed to clarify its biological effects.
To verify the safety and usefulness of RJ, we conducted sister chromatid exchange (SCE) assay, a standard procedure (10) to determine genotoxicity and cytotoxicity in human lymphocytes. To elucidate the effects of RJ at the molecular level, the expressions of pivotal regulatory genes; c-MYC, hTERT, NRF2, HO-1, BCL2, BAX, cyclin E and cyclin B were quantified and analysed by Western blot to clarify its action on cell proliferation, maintenance of telomere/lifespan, antioxidative power, cell survival, cell apoptosis and cell cycle progression. The study was conducted using human lymphocytes, because these cells would grow in rather synchronous cell cycles rather than heterogeneously for primary human cell cultures. We felt that this characteristic would improve our chances of detecting genotoxic and molecular changes.
c-MYC is a multifunctional transcriptional factor, encoded from the c-MYC oncogene, responsible for cell proliferation and cell transformation (11) . It also activates hTERT transcription (12) . Human telomerase reverse transcriptase (hTERT) is a catalytic subunit of enzyme telomerase which maintains telomere length, regulates replicative senescence and cell immortality (13) . NRF2 is a nuclear factor erythroid-2 related factor 2 that induces defence system against oxidative stress (14) , such as heme oxygenase-1 (HO-1). The HO-1 is an inducible heme oxygenase responsible for protecting cells from oxidative stress (15) . BCL2 (B-cell lymphoma 2) is an antiapoptotic protein that blocks program cell death to promote cell survival (16) . BAX (BCL2 associated X protein) is a proapoptotic protein, inducing cell death (17) . Cyclins are regulatory proteins that control cell cycle progression. Cyclin E controls transition from early G1 to S phases (18) , and cyclin B controls from G2 to M phases.
In order to evaluate the effects of RJ on human lymphocytes either strengthening or weakening human cells, we assessed all detected regulatory protein levels as ratios over BAX. Similar to the BCL2/BAX ratio, a rheostat which reflects sensitivity to apoptosis (19), we determined expression of these regulatory proteins: BCL2/BAX, hTERT/ BAX, c-MYC/BAX, NRF2/BAX and HO-1/BAX, as ratios over cell death to evaluate the levels of cell survival, longevity, cell proliferation, antioxidative potential and antioxidant enzyme, respectively. Levels of these expression ratios should increase or vice versa. We hypothesised that the beneficial effect of RJ would enhance cell survival, cell proliferation, antioxidation potentials and maintain telomere length.
Materials and Methods

Analysis RJ composition
Frozen RJ produced by honeybees (Apis mellifera) was purchased from an apiary company certified by the Ministry of Industry, Thailand. Carbohydrate, protein, ash and moisture contents in RJ were measured using AOAC methods (20) . Lipid content extracted with diethyl ether for 24 h in Soxhlet apparatus was determined. Total flavonoid content was analysed by aluminium chloride colorimetric assay (21) . Total phenolic content was evaluated by FolinCiocalteu's reagent (22) . 10-hydroxy-2-decenoic acid, ferulic acid and sinapic acid levels were examined by quantitative high-performance liquid chromatography (HPLC) (23, 24) .
Genotoxic and cytotoxic studies by SCE assay
Fresh blood samples for all experiments were obtained by venipuncture from 6 healthy volunteers, aged 25-35 years with no recent exposure to radiation or drugs. These studies were approved by our institutional ethics committee (MTU-EC-DS-2-067/56). Lymphocyte-enriched buffy coat (from 0.8 ml whole blood) was cultured in 5 ml culture medium containing Roswell Park Memorial Institute medium (RPMI)1640 (Hyclone, USA), fetal bovine serum (Hyclone, USA), autologous plasma, penicillin-streptomycin (Seromed, Germany), phytohemagglutinin (Seromed, Germany) and L-glutamine (Hyclone, USA) using standard blood culture conditions as previously described (25) . At 24 h after initiation of the culture, the lymphocyte cultures were centrifuged for packed cells, and the supernatant medium was removed and saved for reuse after treatment. The remaining lymphocytes were treated with RJ at concentrations of 0.0005, 0.005, 0.05, 0.5 and 5 mg/ml dissolved in 2% V/V dimethylsulfoxide (DMSO) in RPMI 1640 culture medium at 37°C for 3 h. For positive control, the lymphocytes were treated with 0.1 µg/ml doxorubicin (DXR) (Pharmacia and Upjohn company, USA) for 3 h. For negative control, the lymphocytes were treated with RPMI 1640 for 3 h. After treatments, lymphocyte cultures were centrifuged for packed cells. The supernatant medium was discarded, and the saved culture medium was reused. Bromodeoxyuridine (BrdU) solution (Sigma-Aldrich, USA) was added to the culture medium for the final concentration at 5 mM, and cell culture was continued at 37°C in the dark.
Due to cell cycle delay, cells were harvested at 76 h after initiation. Slides were prepared and stained using the fluorescent plus Giemsa technique as previously described (26) . Twenty-five cells per dose per experiment showing the second metaphase-staining pattern were scored from the coded slides for frequencies of SCE. The proliferation index (P.I.) and mitotic index (M.I.) were also evaluated. M.I. was determined by the number of all mitotic cells/1000 cells. P.I. was determined as (MI+2MII+3MIII)/100 cells, where MI is the number of metaphase cells from the first cell cycle (homogeneously-stained chromatids), MII is the number of metaphase cells from the second cell cycle (heterogeneouslystained chromatids), and MIII is the number of metaphase cells from the third cell cycle (mixed homogenously-stained and heterogeneouslystained chromatids) ( Figure 1 ). Three independent experiments were performed for each concentration of the treated compounds.
For statistical analysis, a square root transformation of the SCE data was required to stabilise the variances, according to the procedures of Whorton et al. (27) . The frequency of transformed SCE was expressed as a square root of SCE. Dunnett's t-test was performed to analyse the difference between the means of the treated groups and the means of the control groups using the transformed data. Data are shown as mean ± SEM.
Transformed SCE can be expressed as the equation: 
Determination of cell viability and pivotal gene expressions
Human lymphocytes were isolated by using LymphoprepTM (Stem cell Technologies, Canada). Isolated human lymphocytes were cultured in RPMI medium containing 10% V/V fetal calf serum (GE Health Care Life Science, USA), 1% V/V L-glutamine (Thermo Fisher Scientific, USA), 2% V/V Phytohaemagglutinin (Thermo Fisher Scientific, USA), 1% Penicillin-Streptomycin (Thermo Fisher Scientific, USA) in a 5% CO 2 incubator at 37°C for 24 h. Then, cells were treated with various concentrations of RJ (0.0005, 0.005, 0.05, 0.5 and 5 mg/ ml) for 24 h. RPMI 1640 and 2% V/V DMSO were used as negative controls. DXR (0.2 µg/ml) was used as a positive control.
Determination of cell viability by MTS tetrazolium assay
To determine cell viability, the CellTiter 96® aqueous one solution cell proliferation MTS assay kit (Promega, USA) was used. Briefly, 20 microlitres of the MTS tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium reagent was added to each cell culture well containing treated cells in 100 µl medium, incubated at 37°C for 2 h in a humidified 5% CO 2 . The MTS was reduced by NADH or NADPH which produced by metabolically active cells. The formazan products were formed and measured by the absorbance at 490 nm with a PowerWave™ XS microplate spectrophotometer (BioTek, USA) and calculated for the % cell viability.
(At) is the absorbance of treated cells; (Ac) is the absorbance of the control.
Determination of pivotal gene expressions by Western blot analysis
To determine gene expression at protein level, treated human lymphocytes were harvested and lysed with Ripa lysis buffer (Merck Millipore, USA) containing protease inhibitor cocktail set I (Merck Millipore, USA). The protein samples were boiled and separated on 10% SDS-polyacrylamide denaturing gels (SDS-PAGE), followed by blotting onto nitrocellulose membranes (GE Healthcare, USA) and blocking with the Odyssey blocking buffer (LI-COR, USA). After that, membranes were probed with corresponding primary antibodies. Rabbit primary antibodies were anti-c-MYC, anti-BAX, anti-HO-1 and anti-BCL2 from Cell Signaling, USA. Anti-hTERT and anti-NRF2 were from Merck Millipore, USA. Rabbit anti-β-actin polyclonal antibody (Cell Signaling, USA) was used as an internal control. Membranes were then washed and incubated with LI-COR IRDye 680 mouse anti-rabbit. The protein bands were visualised using Odyssey Fc Imager (LI-COR, USA).
Results
Composition profile of RJ
The frozen RJ sample had pH 4.0 with 65% moisture, 2.5% lipids, 2.2% proteins, 0.2% fibre, no ash and 32% carbohydrates (%wt/wt). Our current samples had lower nutrient contents, especially proteins, lipids, and carbohydrates, compared to that of our previous report using fresh RJ, which had pH 3.5, 67.4% moisture, 12.1% carbohydrate, 4% lipid, 12% proteins and 1% ash (28) . The compositions of RJ from Romania and Bulgaria also reported a higher amount of protein contents at 13% and 15.5%, respectively, and both had pH 3.9 (29) . Total phenolic acid from our RJ sample was 1.8 ± 0.5 mg Gallic acid equivalent/g. Total flavonoids were 0.9 ± 0.1 mg Rutin equivalent/g. Antioxidant activity was 17.9 ± 1.9 μM Trolox equivalent antioxidant capacity/g; Trolox EC 50 = 1103 μM. Ferulic acid and sinapic acid was 2.5 and 0.7 μg/g RJ, respectively. 10-Hydroxydecenoic acid, the active fatty acid, was 8 mg/g RJ.
Genotoxic and cytotoxic activities of RJ treatments for 3 h by SCE assay
To verify in vitro genotoxic and cytotoxic activities of RJ, we conducted the SCE assay in human lymphocytes. As shown in Figure 2 , treatments with RJ (0.0005, 0.005, 0.05, 0.5 and 5 mg/ml) for 3 h had no cytotoxicity to human cells, but the 5 mg/ml treatment induced genotoxicity by a 1.4-fold increase compared to that of RPMI negative control (P < 0.05). Treatment of 2% V/V DMSO, a solvent control, showed a slight increase in SCE levels but there was no significant difference from the RPMI control. The SCE level induced by DXR treatment (0.1 µg/ml), a positive control, was a 2-fold increase (P < 0.05). There was no significant difference between M.I. and P.I. among treatments (Table 1 ). However, there was a slight delay of cell cycle progression from MI to MII caused by the low dose of 0.0005 mg/ml RJ treatment (Figure 3 ). Cell cycle delay was also induced by 2% V/V DMSO solvent and DXR positive control. It is noteworthy that serial dilution of RJ (dissolved in DMSO) with RPMI solvent was prepared and therefore, the concentration of DMSO in RJ at 0.0005 mg/ml was 10 000 times diluted. Consequently, the effect of cell cycle delay resulted from RJ itself while having very little effect from the DMSO. RJ treatments at higher doses showed relatively higher cell cycle progression (higher MII cells than MI cells) as compared to that of the RPMI control.
Effects on cell viability by RJ treatments for 24 h
As shown in Figure 4 , treatments of various concentrations of RJ (0.0005-5 mg/ml) for 24 h significantly decreased cell viability to 78-75% (P < 0.05) compared to untreated control. DXR significantly decreased cell viability to 76%.
Effects of various concentrations of RJ on cell cycle regulatory proteins; cyclin E and cyclin B
There were bell-shaped curves for cyclin E and cyclin B responses to various doses of RJ treatments for 24 h (Figure 5a and b) . Cyclin E and cyclin B levels increased to an optimum at 0.05 mg/ml RJ treatment. In addition, most of the treated cells had much higher cyclin E than cyclin B (Figure 5c ), suggesting that most of the treated cells progressed from G1 to S phases.
Modulation of h-TERT, c-MYC, BCL2, BAX, NRF2 and HO-1 levels in response to various concentrations of RJ treatments for 24 h
As shown in Figure 6 and 7, there was a 2.3-fold increase of hTERT (optimum at 0.05 mg/ml RJ) and followed by a slow decrease. The level of c-MYC protein tended to have a slight dose-dependent decrease (from 1.0-fold to −0.5-fold) with all doses from 0.0005 to 5 mg/ml. For BCL2 and BAX, 0.05 mg/ml RJ treatment increased BCL2 and BAX to maximum levels at 1.3-fold and 1.8-fold, respectively. There was a trend of dose-dependent increase in NRF2 (from 1.0-fold to 1.6-fold). However, the levels of HO-1 tended to decrease (from 1-fold to −0.4-fold) as the dose increased. In contrast, DXR treatment decreased all hTERT (−0.9-fold), c-MYC (−0.7-fold), BCL2 (−0.9-fold), NRF2 (−1.0-fold) and HO-1(−0.6-fold), except increased BAX (1.4-fold) . Overall regulatory protein levels responsible for longevity, cell proliferation, cell survival, antioxidative potentials, antioxidative enzyme and cell death in the form of ratios over BAX To validate the overall effects of RJ on certain regulatory protein levels, we expressed h-TERT, c-MYC, BCL2, HO-1, NRF2 levels in a relationship with BAX as follows: hTERT/BAX, C-MYC/BAX, BCL2/BAX, NRF2/BAX and HO-1/BAX (Figure 8 ). Such evaluation reflects health or weakness (death) in treated cells similar to BCL2/ BAX, a rheostat that regulates life and death (19) . Alternatively, BAX level was used as an internal control to compare different levels of regulatory proteins. As shown in Figure 8 , the results demonstrated that there were dose-dependent decreases of C-MYC/BAX, BCL2/BAX, NRF2/BAX (only at 0.0005-0.5 mg/ml RJ) and HO-1/ BAX ratios with high correlation coefficient (r) equal to (−0.9) to (−1) ( Table 2) . It indicated that the higher the concentration, the lower the ratios of cell proliferation, cell survival and antioxidative enzyme over cell death, or vice versa. For hTERT/BAX, all doses of RJ treatments increased hTERT/BAX without dose-dependency. It maintained high at approximately 1.2-fold (range from 1.3-to 1.1-fold), proposing a longevity potential. The correlation coefficient of h-TERT/BAX was −0.37 (Table 2) suggesting its value was relatively stable. The exception was the NRF2/BAX ratio in which there was a dose-dependent decrease (1.0-fold to 0.7-fold decrease) at low doses of 0.0005-0.5 mg/ml RJ treatments, then, a sharp increase of 1.1-fold appeared at the highest dose of 5 mg/ml RJ.
Our observations indicate that the lowest dose of 0.0005 mg/ml RJ had the highest beneficial effects by maintaining cell proliferation (c-MYC/BAX), cell survival, (BCL2/BAX), antioxidant enzyme level (HO-1/BAX), antioxidative response (NRF2/BAX) at approximately normal level, and enhanced telomerase level ratio (hTERT/ BAX) by 1.3-fold. On the contrary, the highest dose of 5 mg/ml RJ caused more harm, though maintaining the telomere length protection and enhanced antioxidative response (hTERT/BAX and NRF2/BAX = 1.1-fold). It decreased cell proliferation, cell survival and antioxidant enzyme level. The deleterious effects at the highest dose of RJ corresponded with its genotoxicity. In comparison with DXR, the toxicity induced by the highest dose of RJ still maintained hTERT/BAX and increased NRF2/BAX, which empowered cells to fight oxidative damage. On the contrary, DXR decreased all BCL2/ BAX (−0.6-fold), C-MYC/BAX (−0.5-fold), HO-1/BAX (−0.4-fold), hTERT/BAX (−0.7-fold) and NRF2/BAX (−0.7-fold), suggesting its toxicity in promoting cell death, decreasing cell proliferation, decreasing antioxidative response and shortening telomere. Our results also revealed that cells undergoing active proliferation from G1/S phase (at 0.05 mg/ml RJ) activated hTERT, NRF2, BCL2 and also BAX levels. These data indicated that when cells were activated during G1/S cell cycle progression: more cells proliferated and at the same time, more cells entered apoptosis. Therefore, the gene expression levels of hTERT, c-MYC, NRF2, HO-1 and BCL2 alone may not provide informative data on cell status or cell quality. Those gene expression values should be corrected by formulating their ratios over BAX to validate the actual cellular status.
Discussion
Our present study determined levels of genotoxic activity and mechanisms of action of RJ at various doses in human lymphocytes in vitro. It demonstrated that RJ treatments at 0.0005-5 mg/ml (10 000-fold different) for 3 h did not induce cytotoxicity in human lymphocytes, however, a high dose of 5 mg/ml induced genotoxicity (1.4-fold). There was no statistical significance on the P.I. of the treated cells and the control, but there was a trend of increased cell cycle progression from MI to MII with the increasing doses of RJ. By SCE assay, our data indicate that RJ ≤ 0.5 mg/ml was quite safe with no genotoxic nor cytotoxic damage to human cells in vitro. From the assumption that an Asian individual weights 60 Kg and the body is made up of mostly water, we assume that 1 ml in vitro equals to 1 gm of tissue for conversion of in vitro to human doses. Thus, consumption of less than 30 g RJ for a 60 Kg man should be considered safe. However, intake of RJ is prohibited for those with allergies since it may induce anaphylaxis and death.
Treatments of RJ at 0.0005-5 mg/ml for 24 h significantly decreased cell viability by 18-30% with a slight dose-dependent decrease. These results showed a little higher toxicity than those determined by the SCE assay, possibly resulted from the different procedure. All treated cells in the SCE assay were allowed to repair for another 52 h but not for the MTS assay. Western blot analysis demonstrated that RJ had both beneficial and harmful effects, depending on the doses. Our data suggest that RJ treatment at a low dose of 0.0005 mg/ml provided maximum benefits to human cells especially protecting telomere and prolonged lifespan. DXR, in contrast, decreased hTERT/BAX suggesting its shortening telomere leading to shortening lifespan. However, it should be emphasised that the real effective doses of RJ would be dependent upon nutritional content RJ which would be influenced by storage conditions. Our DXR data is in agreement with a report by Li, 2012 demonstrating that DXR treatments in normal human lymphocytes significantly decreased hTERT expression, telomerase activity and shortening telomeres (30) .
Our in vitro mechanistic study of RJ also supports previous in vivo studies. Inoue et al., 2012 reported that dietary RJ reduced oxidative damage: 8-hydroxydeoxyguanine (8-OHdG) in mice and extended survival time (5) . This study provided new insight molecular mechanisms, showing the antioxidative power of RJ through modifying NRF2 and HO-1 levels. In another report, intake of freeze-dry RJ by Drosophila melanogaster decreased their developmental time to adulthood, extended lifespan and increased female fecundity (31) . Our data revealed that RJ induced an increase in hTERT and hTERT/BAX levels, possibly preventing cellular senescence, and extending lifespan. Previous studies already reported that hTERT proteins detected in normal human lymphocytes correlated with telomerase activity (32) . In addition, telomerase-expressing normal human clones extended normal lifespan but not telomerasenegative clones (33) .
In addition, 57 KD protein isolated from RJ stimulated rat hepatocyte proliferation and promoted antiapoptosis (34) . Our study also indicates that RJ enhanced cell proliferation and promoted cell survival by modulating through c-MYC/BAX and BCL/BAX ratios.
Conclusion
RJ at the lowest dose modulated various regulatory gene expressions, promoting cell survival, longevity, antioxidative response and cell proliferation while lowering apoptosis. A summarised model was proposed as shown in Figure 9 . However, at the highest dose, it can harm human cells by inducing genotoxicity, increasing the ratio of cell death while lowering the ratios of cell survival and cell proliferation. Nevertheless, these adverse effects might not be so severe since the highest dose of RJ still enhanced the NRF2/BAX ratio and maintained a slightly higher ratio of hTERT/BAX, preserving cellular defence capacities (Figure 7 ). However, it should be stated that this work was done in vitro although human lymphocytes were used and in vivo studies need to be conducted to validate the results.
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